BioSpace News Archive

The Fact.MR market study on the medical membrane market provides deep dive into key developments in the medical membrane market.

argenx announced that it will host a conference call and audio webcast on Thursday, March 3, 2022 at 2:30 pm CET to discuss its full year 2021 financial results and provide a fourth quarter business update.

The accelerated approval of TARPEYO was for the indication of reduction of proteinuria, which was the endpoint of Part A of the trial, in adult patients with IgA nephropathy with risk of rapid progression, which is characterized as generally UPCR ≥ 1.5 g/g.

SHL Medical and Innovation Zed is pleased to share the news that Innovation Zed’s injection time-tracker connected device, the InsulCheck CONNECT, a device that was designed by SHL Medical, has been selected as a winner of the 2021 Good Design Award.

Orexo AB, announced information about improved market access position for ZUBSOLV® sublingual tablet for opioid dependence.

GliaPharm SA and the Wyss Center announced a collaboration to develop new treatments for Alzheimer’s disease.

Atamyo Therapeutics, a biotechnology company focused on the development of new-generation gene therapies targeting neuromuscular diseases, announced multiple major regulatory and financial milestones for ATA-100, a one-time gene therapy for the treatment of fukutin-related protein limb-girdle muscular dystrophy Type 2I/R9.

COPENHAGEN, Denmark; February 24, 2022 – Genmab A/S summons the Annual General Meeting on Tuesday, March 29, 2022, at 2:00 PM CEST at the Copenhagen Marriott Hotel, KalvebodBrygge 5, DK-1560 Copenhagen V, Denmark.

MannKind Corporation was informed that the U.S. Food and Drug Administration issued an information request to United Therapeutics Corporation earlier this month regarding the New Drug Application for Tyvaso DPI, requesting additional information regarding the pulmonary safety of Tyvaso DPI related to a pending Citizen Petition.

Nautilus Biotechnology, Inc., a company pioneering a single molecule proteome analysis platform, reported financial results for the fourth quarter and fiscal year ended December 31, 2021.